FDA Approves an Adjuvant Targeted Therapy for Post-Surgery RCC Patients, but Questions and Clinical Challenges Remain

Abstract

After years of attempts to find an adjuvant therapy to reduce the risk of renal cell carcinoma recurrence after nephrectomy, we now have an FDA-approved targeted therapy for this indication. There have been numerous negative studies previously, and some felt that VEGF targeted therapy would never gain regulatory approval in the adjuvant setting, however, results of phase III S-TRAC trial have changed all of that.